NCT02248116View on ClinicalTrials.gov

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

September 30, 2000

Conditions
Alzheimer Disease
Interventions
DRUG

Talsaclidine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY